Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two doses of either the Pfizer or Oxford-AstraZeneca vaccine offer similar protection against symptomatic SARS-CoV-2 infection to that coming from natural immunity after infection, an ongoing study of healthcare workers has found.

OUH’s Chief Nurse, Sam Foster, delivers a Pfizer vaccine to a member of staff

None of the 1,456 healthcare workers at Oxford University Hospitals (OUH) NHS Foundation Trust who had received two vaccines had a symptomatic infection when followed up more than 14 days after their second vaccination. The same high level of protection was seen in unvaccinated healthcare workers who had contracted COVID-19 naturally; they had 98% fewer symptomatic infections than unvaccinated individuals who had not been infected before.

Most of the healthcare workers studied had only received one vaccine to date. Protection against symptomatic infection was lower – at 67% – after a first dose of vaccine – received by 11,023 hospital staff.

The findings were the latest data from ongoing analysis of symptomatic and asymptomatic staff testing for SARS-CoV-2 at OUH’s four hospitals and associated facilities. In total, 13,109 healthcare workers have participated.

Of these, 8,285 have received the Pfizer-BioNTech vaccine (1,407 of them two doses) and 2,738 the Oxford-AstraZeneca vaccine (49 of them receiving both doses).

Read the full story on the NIHR Oxford Biomedical Research Centre website

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

20 minutes of daily exercise can keep teens' doctors away

Teenagers should exercise vigorously for at least 20 minutes per day to reap increased cardiorespiratory fitness (CRF), according to a cross-sectional study from the UK led by University of Oxford researchers.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.